LENZ Therapeutics Submits VIZZ® Application to EMA for Presbyopia

Key Takeaways

• EMA MAA for VIZZ was announced March 10, 2026; LENZ called it the fifth ex-U.S. regulatory filing for the product.
• FDA approved VIZZ on July 31, 2025 (NDA 218585) for adult presbyopia; U.S. commercial supply is already underway.
• U.S. efficacy support came from CLARITY Phase 3 trials summarized in FDA Drug Trials Snapshots.
• European commercialization is planned via partnerships; MAA filing is not yet EU authorization.

What did LENZ file with EMA for VIZZ?

According to the company wire, LENZ filed an MAA asking EMA to review VIZZ as the first aceclidine-based eye drop for adult presbyopia. Presbyopia is age-related loss of near vision; LENZ cites a global prevalence estimate of about 1.8 billion people.

Primary disclosure: GlobeNewswire, March 10, 2026.

What is VIZZ’s U.S. approval status?

FDA approved VIZZ on July 31, 2025. The approval package for NDA 218585 lists the indication as treatment of presbyopia in adults and the dosage as one drop in each eye, wait two minutes, then a second drop once daily.

See the FDA approval letter (NDA 218585) and the FDA Drug Trials Snapshots: VIZZ page for trial design and efficacy framing.

Which clinical data support the VIZZ European filing?

FDA’s snapshot states efficacy support from CLARITY-1 and CLARITY-2 (six weeks; 466 patients with presbyopia at 42 U.S. sites) and safety support from CLARITY-3 (26 weeks; 361 patients at 40 U.S. sites).

• Primary efficacy concept: ≥3-line (15-letter) near improvement at 40 cm without ≥5-letter distance loss at 4 m, assessed three hours post-dose on Day 1.
• Comparators: brimonidine (CLARITY-1) or vehicle (CLARITY-2).
• Company communications also describe onset within about 30 minutes and duration up to about 10 hours in CLARITY summaries.

How does LENZ plan to commercialize VIZZ in Europe?

LENZ said it intends to pursue European commercialization through strategic partnerships, alongside existing regional deals covering Greater China, Korea and Southeast Asia, Canada, and the Middle East. A later May 11, 2026 corporate update also noted an April 2026 MHRA filing for the United Kingdom.

European market-access teams should track CHMP questions, partnership announcements, and any UK divergence after MHRA review—not only the EMA clock.

Why does a VIZZ EMA filing matter for eye-care markets?

If authorized, VIZZ would add a pharmacologic near-vision option in Europe beyond spectacles, contact lenses, and surgical approaches. Aceclidine is a cholinergic muscarinic agonist that creates a pinhole pupil effect to deepen depth of focus.

Competitive dynamics will depend on tolerability (for example pupil-related adverse events), real-world duration, and reimbursement—not on MAA acceptance alone.

What remains unproven in Europe?

EMA has not issued a CHMP opinion or European Commission decision for VIZZ. U.S. Phase 3 success does not automatically equal EU labeling. Partnership economics, pricing, and uptake among ophthalmologists and optometrists remain open.

Until authorization, European clinicians should treat VIZZ as FDA-approved in the United States and under review in the EU, not as an available EU medicine.

Related NovaPharma coverage

• Privosegtor EMA PRIME for Optic Neuritis
• EMA CHMP Backs Four New Medicines
• Potential FDA Approval Eye Drug Coverage

Frequently Asked Questions

Primary Sources

1. GlobeNewswire — LENZ VIZZ EMA MAA submission
2. FDA — Drug Trials Snapshots: VIZZ
3. FDA — VIZZ NDA 218585 approval letter